Get the Stockscreener App
16.44
1.62%
-0.27
Alto Neuroscience Inc stock is traded at $16.44, with a volume of 166.53K.
It is down -1.62% in the last 24 hours and down -2.95% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$16.71
Open:
$16.84
24h Volume:
166.53K
Relative Volume:
0.52
Market Cap:
$510.73M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-7.6252
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
+16.51%
1M Performance:
-2.95%
6M Performance:
+416.98%
1Y Performance:
+421.90%
1-Day Range:
$15.97
$16.95
1-Week Range:
$13.91
$16.95
52-Week Range:
$1.60
$20.91
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
16.44 | 519.12M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Alto Neuroscience (NYSE:ANRO) Trading 9.8% HigherShould You Buy? - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Yahoo Finance
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - BioSpace
Alto Neuroscience announces $75 million ATM offering - MSN
Aug Volume: Can Andretti Acquisition Corp. II Equity Warrant maintain its current growth rate2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0% - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Calls: What chart patterns are forming on VNOPRNTrade Signal Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Alto Neuroscience receives patent for depression treatment method By Investing.com - Investing.com Nigeria
Alto Neuroscience issued patent for ALTO-207 - TipRanks
Alto Neuroscience Granted Patent for New Method of Treating Depression With ALTO-207 - marketscreener.com
Alto Neuroscience receives patent for depression treatment method - Investing.com
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire
Short Squeeze: Can Alto Neuroscience Inc stock deliver strong Q4 earningsPortfolio Gains Summary & Reliable Price Breakout Signals - Bộ Nội Vụ
Alto Neuroscience, Inc. Presents New Data At the 64Th Annual Meeting of the American College of Neuropsychopharmacology - marketscreener.com
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology - Business Wire
Chart Watch: Will Alto Neuroscience Inc stock test record highs in 2025Weekly Trade Review & AI Optimized Trade Strategies - Bộ Nội Vụ
Alto Neuroscience (NYSE:ANRO) Trading Up 8.1% – Should You Buy? - Defense World
Does Alto Neuroscience Inc. stock trade at a discount to peers2025 Retail Activity & Step-by-Step Trade Execution Guides - Улправда
What margin trends mean for Alto Neuroscience Inc. stockDividend Hike & Trade Opportunity Analysis - Улправда
Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.1%What's Next? - MarketBeat
Why Alto Neuroscience Inc. stock could be next big winner2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - Улправда
How Alto Neuroscience Inc. stock performs in stagflationSell Signal & Consistent Profit Trading Strategies - Улправда
Is Alto Neuroscience Inc. stock bottoming after sell offWeekly Market Report & Consistent Income Trade Ideas - Улправда
Is Alto Neuroscience Inc. stock a good choice for value investorsPortfolio Diversification Tips & Low Cost Capital Gains - ulpravda.ru
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO) - MSN
Is Alto Neuroscience Inc. stock supported by strong fundamentals2026 world cup usa national team qualification young talents high defensive line group prediction guide - ulpravda.ru
Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating - Investing.com Canada
Chardan Capital Doubles Price Target for ANRO to $30 and Maintai - GuruFocus
Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00 - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why - Defense World
Alto Neuroscience (NYSE:ANRO) Shares Down 6%What's Next? - MarketBeat
Alto Neuroscience, Inc.'s (NYSE:ANRO) Institutional Investors Lost 10% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6%Here's Why - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Yahoo Finance
Alto Neuroscience Stock 9-Day Winning Spree: Stock Climbs 51% - Trefis
Will Alto Neuroscience Inc. stock continue upward momentumJuly 2025 Outlook & Fast Moving Stock Trade Plans - Улправда
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Volume Summary: What sentiment indicators say about Alto Neuroscience Inc stockJuly 2025 Update & Accurate Trade Setup Notifications - moha.gov.vn
Is Alto Neuroscience Inc. stock safe for conservative investors2025 Institutional Moves & AI Forecast for Swing Trade Picks - Улправда
Alto Neuroscience Stock Rockets 51% With 8-Day Winning Streak - Trefis
How Alto Neuroscience Inc. stock benefits from global expansion2025 Biggest Moves & Verified Momentum Stock Watchlist - DonanımHaber
Will Alto Neuroscience Inc. stock sustain uptrend momentum2025 Winners & Losers & Daily Stock Trend Watchlist - DonanımHaber
Stock Analysis: Is Alto Neuroscience Inc. stock a good choice for value investors2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
Why Alto Neuroscience Inc. stock remains undervaluedJuly 2025 Volume & Consistent Profit Alerts - Улправда
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):